- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Di | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients | 63 | At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS... ► Artikel lesen | ||
| Di | Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 176 | GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference... ► Artikel lesen | ||
| Di | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 107 | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | ||
| Di | BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates | 132 | Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended... ► Artikel lesen | ||
| Di | Zapp Electric Vehicles Group Limited: Zapp EV to Display i300 in Selfridges London Through New Partnership with Smartech Retail Group | 295 | Performance urban electric two-wheeler coming to Oxford Street as next step in plan to grow Zapp's retail networkLONDON, Aug. 12, 2025(OTCQB: ZAPPF) ("Zapp EV" or the "Company"), owner of "Zapp", the... ► Artikel lesen | ||
| Di | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | 254 | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | ||
| Di | Hubbell Inc.: Hubbell to Acquire DMC Power | 94 | Shelton, CT, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Hubbell to Acquire DMC Power Provider of connectors and tooling for utility substation and transmission marketsComplementary technology enhances Hubbell's... ► Artikel lesen | ||
| Di | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update | 94 | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | ||
| Di | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 516 | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | ||
| Di | Wood Mackenzie launches Prospect Valuation and AI-powered Analogues to unlock advantaged oil and gas resources | 306 | Wood Mackenzie launches Prospect Valuation and AI-powered Analogues to unlock advantaged oil and gas resources
New capabilities help Upstream companies optimise investments in an evolving energy... ► Artikel lesen | ||
| Di | ZenaTech Inc.: ZenaTech Reports Over 500% Increase in Year-Over-Year Revenue for Second Quarter of 2025 and Over 250% Increase in Revenue for the First Six Months of Year | 185 | VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology business solution provider specializing in AI (Artificial... ► Artikel lesen | ||
| Di | Mobilicom Limited: Mobilicom Reports Financial and Operational Results for the Six Months Ended June 30, 2025 | 186 | Momentum accelerates with $1.5 million in revenue for H1 2025 and an order backlog of $1.6 million as of June 30, bringing the combined total to $3.1 million - already approaching full-year 2024 revenue... ► Artikel lesen | ||
| Di | Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 48 | - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis... ► Artikel lesen | ||
| Di | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | 203 | FDA Accepted the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST... ► Artikel lesen | ||
| Di | AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease | 212 | MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced... ► Artikel lesen | ||
| Di | Greenland Lithium Pegmatite Field Significantly Expanded by Brunswick Exploration | 242 | MONTREAL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; "BRW" or the "Company") is pleased to announced that it has identified the country's... ► Artikel lesen | ||
| Di | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 | 256 | Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type... ► Artikel lesen | ||
| Di | Trident Resources Corp.: Trident Resources Announces the Acquisition of Claims from Eagle Plains Resources Within the La Ronge Gold Belt in Saskatchewan, Canada | 300 | Vancouver, BC, Aug. 12, 2025) (OTCQB:
TRDTF) ("Trident" or the "Company") is pleased to announce that it has signed a non-arm's length agreement (the "Agreement") with Eagle Plains Resources... ► Artikel lesen | ||
| Di | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights | 59 | Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted... ► Artikel lesen | ||
| Di | OTC Markets Group Welcomes First Phosphate Corp. to OTCQX | 65 | NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced First Phosphate... ► Artikel lesen | ||
| Di | U.S. Energy Corp. Reports Second Quarter 2025 Results and Provides Operational Update | 320 | HOUSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- U.S. Energy Corporation (NASDAQ: USEG, "U.S. Energy" or the "Company"), a growth-focused energy company engaged in the development and operation of high-quality... ► Artikel lesen | ||
| Di | Climb Bio, Inc.: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates | 263 | Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in... ► Artikel lesen | ||
| Di | Autolus Therapeutics plc: Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | 475 | Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and... ► Artikel lesen | ||
| Di | X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership | 127 | $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman... ► Artikel lesen | ||
| Di | eToro Group Ltd.: eToro Reports Second Quarter 2025 Results | 746 | Net Contribution grew by 26% year-over-year to $210 millionAssets Under Administration grew by 54% year-over-year to $17.5 billionFunded accounts grew by 14% year-over-year to 3.63 million NEW YORK... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .